...
首页> 外文期刊>The American surgeon. >What is the Optimal Timing for Liver Surgery of Resectable Synchronous Liver Metastases from Colorectal Cancer?
【24h】

What is the Optimal Timing for Liver Surgery of Resectable Synchronous Liver Metastases from Colorectal Cancer?

机译:来自结肠直肠癌可重型同步肝转移酶的肝脏手术的最佳时间是什么?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The optimal timing of the surgical strategy for colorectal cancer (CRC) presenting with resectable synchronous liver metastases remains unclear and controversial. The aim of this study was to compare simultaneous with staged resection, with respect to morbidity, mortality, and prognosis, including recurrence. A total of 107 patients who underwent initial hepatic resection for resectable synchronous liver metastasis from colorectal cancer were retrospectively analyzed. The 5-year disease-free survival rates were 16.4 per cent in the simultaneous group, and 24.0 per cent in the staged group (P=0.5486). The 5-year overall survival rates were 70.7 per cent in the simultaneous group and 67.9 per cent in the staged group (P=0.8254). Perioperative chemotherapy did not have a significant effect. Tumor depth of CRC (>= pT4) was the only key factor influencing prognosis. Postoperative intestinal anastomotic leakage occurred in nine patients (8.4%). On multivariate analysis, simultaneous surgery was shown to be the only independent risk factor for the occurrence of postoperative intestinal anastomotic leakage (P=0.0163). In conclusion, neither timing of hepatic resection (simultaneous or staged) nor perioperative chemotherapy represented significant prognostic factors. The simultaneous surgery was the only independent risk factor for intestinal anastomotic leakage. Therefore, we recommend staged hepatic surgery for synchronous CRC and liver metastasis from colorectal cancer.
机译:结肠直肠癌(CRC)外科癌症(CRC)的最佳定时呈现可重置同步肝转放酶尚不清楚和争议。本研究的目的是与分阶段切除同时进行比较,涉及发病率,死亡率和预后,包括复发。回顾性分析了总共107名接受初始肝切除的初始肝切除的患者。在同时组的5年的易病存活率为16.4%,分阶段组24.0%(p = 0.5486)。同时组的5年的总体存活率为70.7%,分期组中67.9%(P = 0.8254)。围手术期化疗没有显着效果。 CRC(> = Pt4)的肿瘤深度是影响预后的关键因素。术后肠吻合渗透发生九个患者(8.4%)。在多变量分析中,显示同时手术是术后肠吻合泄漏发生的唯一独立危险因素(P = 0.0163)。总之,肝切除术(同时或分阶段)和围手术期的时序既不是显着的预后因素。同时手术是肠道吻合口渗漏的唯一独立危险因素。因此,我们建议与结直肠癌同步CRC和肝转移的分阶段肝脏手术。

著录项

  • 来源
    《The American surgeon.》 |2017年第1期|共9页
  • 作者单位

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

    Osaka Med Coll Hosp Dept Gen &

    Gastroenterol Surg 2-7 Daigaku Machi Takatsuki Osaka 5698686;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 外科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号